71953-80-5
Chemical Structure
Thromboxane B3
- CAS No.: 71953-80-5
- Formula:C20H32O6
- Molecular Weight:368.46
IUPAC Name: (Z)-7-((2R,3S,4S)-4,6-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)tetrahydro-2H-pyran-3-yl)hept-5-enoic acid
InChIKey: OYPPJMLKAYYWHH-NXJDUNGTSA-N
SMILES: O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C/C=C\CC)OC(O)C[C@@H]1O
Biological Activity: Thromboxane B3 is an eicosanoid and the stable hydrolysis product of thromboxane A3, which is synthesized from eicosapentaenoic acid by cyclooxygenase (COX) and thromboxane synthase. Thromboxane B3 participates in inflammatory cell regulation, tumorigenesis and cell proliferation processes. Elevated levels of Thromboxane B3 correlate with high-risk regions of esophageal cancer. Thromboxane B3 can be used in studies related to bladder cancer, renal cell carcinoma and esophageal squamous cell carcinoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Thromboxane B3 | 95.0% | Thromboxane B3 is an eicosanoid and the stable hydrolysis product of thromboxane A3, which is synthesized from eicosapentaenoic acid by cyclooxygenase (COX) and thromboxane synthase. Thromboxane B3 participates in inflammatory cell regulation, tumorigenesis and cell proliferation processes. Elevated levels of Thromboxane B3 correlate with high-risk regions of esophageal cancer. Thromboxane B3 can be used in studies related to bladder cancer, renal cell carcinoma and esophageal squamous cell carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Deng S, et al. Profiling the Chemical Exposomic Landscape of Esophageal Squamous Cell Carcinoma. Environmental science & technology. 2025 Sep 23;59(37):19705-19718.
- [2]. Gong WJ, et al. Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling. Translational oncology. 2022 May;19:101393.
- [3]. Wang Z, et al. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma. BMC cancer. 2019 Dec 05;19(1):1195.
Keywords
